Values First Advisors, Inc. Prometheus Biosciences, Inc. Transaction History

Values First Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $475,502 - $580,428	-4,596 Reduced 68.63%	2,101 $225,000
Q4 2022 Jan 20, 2023	SELL	$36.06 - $117.21 $68,225 - $221,761	-1,892 Reduced 22.03%	6,697 $0
Q3 2022 Dec 02, 2022	BUY	$28.17 - $59.01 $19,211 - $40,244	682 Added 8.63%	8,589 $507,000
Q2 2022 Jul 20, 2022	BUY	$22.39 - $38.94 $42,518 - $73,947	1,899 Added 31.61%	7,907 $223,000
Q1 2022 May 03, 2022	BUY	$30.13 - $50.0 $181,021 - $300,400	6,008 New	6,008 $227,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.